{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:49:59Z","timestamp":1777884599067,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Background\/objective: The efficacy of interleukin-6 (IL-6) inhibitors in hospitalized patients with severe coronavirus disease 2019 (COVID-19) pneumonitis is unclear. Method: This retrospective, observational cohort study included patients hospitalized at a community hospital with COVID-19 pneumonia from March 2020 to May 2020. All patients were treated with standard of care (SOC), and a nonrandomly selected subset of patients also received an IL-6 inhibitor. The primary outcome was clinical response, defined as an improvement of at least 2 categories relative to baseline on a 7-category ordinal scale up to hospital discharge or 30 days. In adjusted analyses, logistic and linear regression models were conducted, controlling for covariates of hospital length of stay (LOS), intensive care unit (ICU) care, ICU LOS, gender, age, race, and Charlson Comorbidity Index. Results: A total of 133 patients met inclusion criteria. In all, 30 patients received an IL-6 inhibitor plus SOC. There was no statistical difference in clinical outcome between groups as 76.7% in the SOC alone group and 70.0% in the IL-6 inhibitor group met the defined endpoints for clinical response ( P = 0.477). In the adjusted analysis, patients treated with IL-6 inhibitors were approximately 4 times more likely to meet the primary endpoint compared with patients with SOC alone (adj. odds ratio = 4.325; P = 0.038, 95% confidence interval = [1.09-17.18]). Conclusions: Compared with SOC alone, IL-6 inhibitors were not associated with a significant clinical response. However, after adjusting for covariates, this study suggests that the initiation of IL-6 inhibitors in patients with early COVID-19 pneumonitis before progression to the ICU may be associated with improved clinical status.<\/jats:p>","DOI":"10.1177\/87551225221104323","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T05:36:52Z","timestamp":1656913012000},"page":"255-263","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Experience With Interleukin-6 Receptor Antagonists in Patients With COVID-19 Admitted to a Community Hospital"],"prefix":"10.1177","volume":"38","author":[{"given":"Kyle","family":"Manning","sequence":"first","affiliation":[{"name":"University of Utah Health, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Whitman","sequence":"additional","affiliation":[{"name":"Infirmary Health, Mobile, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8348-0895","authenticated-orcid":false,"given":"Lindsey","family":"Hohmann","sequence":"additional","affiliation":[{"name":"Harrison School of Pharmacy, Auburn University, Auburn, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-5923","authenticated-orcid":false,"given":"Jessica","family":"Tubbs","sequence":"additional","affiliation":[{"name":"East Alabama Rheumatology Center, East Alabama Medical Center, Opelika, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-4023","authenticated-orcid":false,"given":"Darrell","family":"Childress","sequence":"additional","affiliation":[{"name":"East Alabama Medical Center, Opelika, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Leon de la Rocha","sequence":"additional","affiliation":[{"name":"Edward Via College of Osteopathic Medicine, Auburn, AL, USA"},{"name":"Premier Rheumatology of Alabama, Auburn, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"bibr1-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202008-3265OC"},{"key":"bibr2-87551225221104323","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255-2273. Accessed November 30, 2020. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMra2026131.","DOI":"10.1056\/NEJMra2026131"},{"key":"bibr3-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1002\/art.41285."},{"key":"bibr4-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0640-2"},{"key":"bibr5-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0629-x"},{"key":"bibr6-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"bibr7-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.04.041"},{"key":"bibr8-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25948"},{"key":"bibr9-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.009"},{"key":"bibr10-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x"},{"key":"bibr11-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015432"},{"key":"bibr12-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004602"},{"key":"bibr13-87551225221104323","unstructured":"Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv. Published March 2020. Updated March 5, 2020. Accessed August 23, 2020. http:\/\/chinaxiv.org\/abs\/202003.00026."},{"key":"bibr14-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6252."},{"key":"bibr15-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30173-9"},{"key":"bibr16-87551225221104323","unstructured":"National Institutes of Health (NIH) Clinical Center. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA). NCT04320615. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2020. Updated July 31, 2020. Accessed August 23, 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04320615."},{"key":"bibr17-87551225221104323","unstructured":"National Institutes of Health (NIH) Clinical Center. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). NCT04372186. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2020. Updated November 4, 2020. Accessed November 30, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04372186."},{"key":"bibr18-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433."},{"key":"bibr19-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.11.21249258."},{"key":"bibr20-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6615"},{"key":"bibr21-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6820"},{"key":"bibr22-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836"},{"key":"bibr23-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700."},{"key":"bibr24-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2100217"},{"key":"bibr25-87551225221104323","unstructured":"National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Updated December 17, 2020. Accessed February 23, 2021. https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"bibr26-87551225221104323","unstructured":"Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. COVID-19 guideline, part 1: treatment and management. Version 3.5.1. Accessed December 20, 2020. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/."},{"key":"bibr27-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003321"},{"key":"bibr28-87551225221104323","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3742"},{"key":"bibr29-87551225221104323","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225221104323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225221104323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225221104323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:31:06Z","timestamp":1777602666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225221104323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/87551225221104323"],"URL":"https:\/\/doi.org\/10.1177\/87551225221104323","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]}}}